These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32299860)

  • 21. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
    Han MK; Criner GJ; Dransfield MT; Halpin DMG; Jones CE; Kilbride S; Lange P; Lettis S; Lipson DA; Lomas DA; Martin N; Wise RA; Singh D; Martinez FJ
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1237-1243. PubMed ID: 32584168
    [No Abstract]   [Full Text] [Related]  

  • 22. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S; Maltais F; Tombs L; Fahy WA; Vahdati-Bolouri M; Locantore N; Riley JH
    Int J Chron Obstruct Pulmon Dis; 2018; 13():203-215. PubMed ID: 29386889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
    Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial.
    Risebrough NA; Mursleen S; Ndirangu K; Shah D; Martin A; Schroeder M; Ismaila AS
    Respir Med; 2024 Sep; 231():107694. PubMed ID: 38844004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF; Beeh KM; Schultze M; Kossack N; Richter LM; Claussen J; Compton C; Noorduyn SG; Ismaila AS; Requena G
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1835-1848. PubMed ID: 39140078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND; Woodcock A; Collier S; Leather DA; New JP; Crawford J; Harvey C; Vestbo J; Boucot I
    Respir Med; 2019 Feb; 147():58-65. PubMed ID: 30704700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 29. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.
    Pascoe SJ; Lipson DA; Locantore N; Barnacle H; Brealey N; Mohindra R; Dransfield MT; Pavord I; Barnes N
    Eur Respir J; 2016 Aug; 48(2):320-30. PubMed ID: 27418551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM; Kalberg CJ; Galkin DV; Zhu CQ; Church A; Riley JH; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
    Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
    Respir Investig; 2024 Jul; 62(4):685-694. PubMed ID: 38796907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
    Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH
    Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
    Dransfield MT; Crim C; Criner GJ; Day NC; Halpin DMG; Han MK; Jones CE; Kilbride S; LaFon D; Lipson DA; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Lange P
    Ann Am Thorac Soc; 2021 May; 18(5):788-798. PubMed ID: 33108212
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
    McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
    Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
    Boulet LP; Abbott C; Brusselle G; Edwards D; Oppenheimer J; Pavord ID; Pizzichini E; Sagara H; Slade D; Wechsler ME; Gibson PG
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1244-1253.e8. PubMed ID: 38309696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.